XML 40 R45.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total | $ 54,851 | $ 21,958 | $ 17,548 | $ 8,071 | $ 26,837 | $ 23,562 | $ 21,416 | $ 12,637 | $ 102,428 | $ 84,452 | $ 36,567
Kite Pharma, Inc. ("Kite") |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 34,350 | 25,517 |
Kite Pharma, Inc. ("Kite") | Recognition of upfront fee |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 24,977 | 18,545 |
Kite Pharma, Inc. ("Kite") | Research services |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 9,373 | 6,972 |
Sanofi |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 22,680 | 13,516 | 12,258
Sanofi | Recognition of upfront fee |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 3,494 | 4,013 | 1,769
Sanofi | Research services |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 6,367 | 9,503 | 10,489
Sanofi | Milestone achievement |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 12,819 | 0 | 0
Pfizer SB-525 |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 39,359 | 37,810 | 17,008
Pfizer SB-525 | Recognition of upfront fee |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total | $ 8,700 |  |  |  |  |  |  |  | 15,697 | 37,810 | 17,008
Pfizer SB-525 | Milestone achievement |  |  |  |  |  |  |  |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | $ 23,662 | $ 0 | $ 0

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |